Skip to Content

Join the 'Lonsurf' group to help and get support from people like you.

Lonsurf News

Speed Up the 'Cancer Moonshot,' Doctors Urge

Posted 18 days ago by Drugs.com

TUESDAY, Oct. 31, 2017 – The Cancer Moonshot Initiative now has a detailed road map designed to cram a decade's worth of medical advancement into half that time. A new report, authored by more than 50 leading U.S. cancer doctors, highlights 13 priority areas for improving the medical response to cancer, along with measurable goals and a specific timeline for meeting each of those objectives. The plan is intended to help "accelerate existing progress so that we deliver in five years what would have historically taken 10," said Dr. Cliff Hudis, chief executive officer of the American Society of Clinical Oncology and co-author of the report. It was created by The Lancet Oncology Commission on Future Research Priorities in the USA. In late 2016, Congress appropriated $1.8 billion for cancer research funding over the next seven years for the so-called Cancer Moonshot, said commission ... Read more

Related support groups: Cancer, Methotrexate, Breast Cancer, Prostate Cancer, Fluorouracil, Gleevec, Lung Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer, Melanoma, Xeloda, Tasigna, Sprycel, Hydroxyurea, Herceptin, Mercaptopurine, Cervical Cancer, Hydrea, Cisplatin, Carboplatin

Many Cancer Patients Skimp on Treatment Due to Cost

Posted 24 Oct 2017 by Drugs.com

TUESDAY, Oct. 24, 2017 – The high cost of cancer care in the United States has led more than one-quarter of patients to cut back on some part of their treatment, a new survey reveals. Commissioned by the American Society of Clinical Oncology (ASCO), the report found that 27 percent of cancer survivors or close relatives of a cancer patient said they'd skipped doctor visits or taken other steps to reduce health costs. To save money, nearly one in 10 said they had avoided doctor appointments. Eight percent had refused treatment; postponed filling or not filled prescriptions; or skipped doses of prescribed medications. And 7 percent said they had cut pills in half, according to the survey of more than 4,000 adults. Such measures can jeopardize treatment success, ASCO says. "We should all be alarmed that Americans are potentially risking not only their health, but also their lives, due to ... Read more

Related support groups: Cancer, Depo-Provera, Provera, Methotrexate, Breast Cancer, Lupron, Medroxyprogesterone, Tamoxifen, Arimidex, Fluorouracil, Lupron Depot, Femara, Gleevec, Lung Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer, Anastrozole, Votrient, Letrozole, Tarceva

Publicly Funded Cancer Trials Gained Americans 3 Million More Years

Posted 6 Jun 2017 by Drugs.com

TUESDAY, June 6, 2017 – Public-funded trials have significantly extended the lives of people diagnosed with cancer, according to new research. SWOG, the clinical trials network funded by the U.S. National Cancer Institute (NCI), has involved more than 200,000 patient volunteers. These trials have led to approval of 14 new cancer drugs and more than 100 changes to cancer care standards. All told, the clinical trials studied extended life by 3.34 million years, the study found. SWOG estimates the dollar return on investment from federal funding at $125 for each year of life gained. "A lot of people with cancer have lived longer because of the therapies tested in our publicly funded trials," study leader Joseph Unger said in a SWOG news release. He is an assistant member of the Fred Hutchinson Cancer Research Center's Cancer Prevention Program in Seattle. "At the same time, the cost of ... Read more

Related support groups: Cancer, Depo-Provera, Provera, Methotrexate, Breast Cancer, Accutane, Lupron, Prostate Cancer, Medroxyprogesterone, Tamoxifen, Tretinoin, Arimidex, Fluorouracil, Lupron Depot, Femara, Gleevec, Lung Cancer, Rituxan, Isotretinoin, Colorectal Cancer

U.S. Pays Highest Prices for Cancer Meds: Study

Posted 6 Jun 2016 by Drugs.com

MONDAY, June 6, 2016 – The United States pays the highest prices in the world for generic and brand-name cancer drugs, a new study has found. However, as the world's wealthiest nation, the United States is better able to pay for those pricey drugs than poorer countries with somewhat lower medication prices, added study lead author Dr. Daniel Goldstein. People in China and India are much less able to afford cancer drugs than Americans, he said, even though U.S. monthly drug prices are about three to six times higher in the United States. That doesn't mean America came out on top in overall drug affordability, however. Developed nations such as Australia, England and Israel had the "best deal" in the world on cancer drugs, thanks to government programs that regulate drug pricing, the study found. "America is the wealthiest nation, but its drug prices are significantly higher – so much ... Read more

Related support groups: Cancer, Depo-Provera, Provera, Methotrexate, Breast Cancer, Accutane, Lupron, Medroxyprogesterone, Tamoxifen, Arimidex, Tretinoin, Fluorouracil, Lupron Depot, Femara, Gleevec, Lung Cancer, Rituxan, Isotretinoin, Colorectal Cancer, Anastrozole

'Precision' Cancer Treatment May Extend Lives

Posted 20 May 2016 by Drugs.com

THURSDAY, May 19, 2016 – "Precision" cancer treatment that's guided by genetic clues from the patient's own tumor appears to outperform traditional chemotherapy, a new research review finds. Patients given precision – or personalized – treatment experienced a tumor shrinkage rate six times that attained by regular chemotherapy. But, that only happened if doctors used genetic information to choose the appropriate targeted therapy, said lead researcher Maria Schwaederle. Those patients also experienced nearly double the length of time before their cancer resumed growing, according to the analysis of nearly 350 clinical trials. "It is not just that the therapies are better, but that targeted therapies must be given to the right patients," said Schwaederle, who's with the University of California, San Diego School of Medicine's Center for Personalized Cancer Therapy. She will present ... Read more

Related support groups: Cancer, Methotrexate, Breast Cancer, Accutane, Tretinoin, Fluorouracil, Gleevec, Lung Cancer, Isotretinoin, Colorectal Cancer, Claravis, Skin Cancer, Tarceva, Xeloda, Tasigna, Revlimid, BCG, Zytiga, Sprycel, Herceptin

Lonsurf Approved for Advanced Colon Cancer

Posted 29 Sep 2015 by Drugs.com

TUESDAY, Sept. 22, 2015 – The combination pill Lonsurf (trifluridine and tipiracil) has been approved by the U.S. Food and Drug Administration to treat advanced colon cancer for people who aren't responding to other treatments, the agency said Tuesday in a news release. Colon cancer is the third most common cause of non-skin cancer in the United States, the FDA said, citing the U.S. National Cancer Institute. It's still the second most common cause of cancer death behind lung cancer, although rates have been declining, in part, due to increased screening for the disease. Lonsurf was evaluated in clinical trials involving some 800 people with previously treated advanced colorectal cancer. Those who took Lonsurf lived an average of more than 7 months, compared to 5.3 months for those who took a placebo. The drug's most common side effects include anemia, a drop in infection-fighting ... Read more

Related support groups: Colorectal Cancer, Lonsurf, Tipiracil/trifluridine

FDA Approves Lonsurf (tipiracil and trifluridine) for Advanced Colorectal Cancer

Posted 29 Sep 2015 by Drugs.com

September 22, 2015 – The U.S. Food and Drug Administration today approved Lonsurf (a pill that combines two drugs, trifluridine and tipiracil) for patients with an advanced form of colorectal cancer who are no longer responding to other therapies. “The past decade has brought a new understanding around colorectal cancer, in how we can both detect and treat this often devastating disease,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “But there are many patients who still need additional options, and today’s approval is a testament to the FDA’s commitment to work with companies to develop new drugs in disease areas where unmet needs remain.” Colorectal cancer is the third most common non-skin cancer in men and women in the U.S., according to the National Cancer Institute. While still the seco ... Read more

Related support groups: Colorectal Cancer, Lonsurf, Tipiracil/trifluridine

Ask a Question

Further Information

Related Condition Support Groups

Colorectal Cancer

Lonsurf Patient Information at Drugs.com